A 4kg result at exactly the right moment
Calocurb chief executive Sarah Kennedy went on the Mike Hosking Breakfast on 21 July 2026 with a number designed to make people pay attention. Participants in a new clinical study taking the company’s supplement lost an average of nearly four kilograms over six months, against less than half a kilogram for those on placebo. Kennedy said the results had “changed the conversation around weight loss”, describing a product that stimulates a natural hormone to make people eat less while preserving lean muscle.
Four kilograms is not Ozempic territory. Prescription semaglutide trials show 10 to 15 percent body weight loss. But Calocurb’s pitch has never been to beat the injectables head to head, and that restraint is exactly why the commercial story holds up.
What it actually is
Calocurb’s active ingredient is Amarasate, a botanical extract derived from bitter hops grown in Motueka, developed by Plant and Food Research over more than a decade. As explained on RNZ in January 2026, the science works by triggering the gut to release GLP-1 and two other appetite-suppressing hormones, CCK and PYY, which signal fullness to the brain.
In August 2024, Kennedy framed the difference plainly. Pharmaceutical companies chased synthetic peptide replacement through GLP-1 agonist injectables; Calocurb went after stimulating the body’s own release. She claimed in 2024 it was the only supplement clinically proven to stimulate three appetite-suppressing hormones at 600 percent above base level, backed by 14 years of work and $30 million in funding, with independent double-blind trials published in peer-reviewed journals.
That matters because a supplement clears a lower evidentiary bar than a drug. The originating source here is a radio interview, not a published paper, and the trial’s sample size and journal have not been disclosed. Take the 4kg figure as a credible signal, not a settled scientific fact.
The gap Pharmac left wide open
Here is the structural opportunity. As of May 2026, Pharmac has not funded Wegovy or Mounjaro for weight loss. Medsafe has approved both, and the Obesity Treatment Advisory Group recommended in December 2025 that semaglutide be funded as high priority for chronic weight management. Funding has not followed. The drugs sit on the Options for Investment List, which is bureaucratic language for the queue.
That leaves a large and growing population with no affordable prescription route. The 2024/25 New Zealand Health Survey, published in November 2025, found 34.2 percent of adults were obese, up from 31.3 percent in 2019/20. Only 31 percent of adults were at a healthy weight. In the most deprived neighbourhoods, 46.8 percent of adults were obese, against 27.6 percent in the least deprived.
When the state declines to fund something and demand keeps climbing, a private market fills the space. Prescription GLP-1 drugs cost between $500 and over $1,000 a month in the US. Calocurb’s new Clinical product sells at US$119.99 a month, no prescription required. That price point, and the absence of a regulatory gate, is the whole commercial thesis.
The clever bit is the off-ramp
Calocurb’s smartest positioning is not as a rival to Ozempic but as the step after it. In 2024, Kennedy said practitioners were already using it as patients came off GLP-1 agonists, because it restimulates the body’s own hormone production and can act as “a safety net” against the weight rebound people report after stopping the injectables.
That is commercially shrewd. Millions of people start expensive injectables and then stop, whether through cost, side effects or supply. Calocurb doesn’t need to win the acute obesity fight to capture a slice of that churn. It just needs to be the affordable maintenance option that keeps the gut-brain signal working once the needle is put away.
Why this is a genuine Kiwi win
The temptation with a supplement story is scepticism, and the honest caveats are real. This is not a pharmaceutical, the comparison to Ozempic should not be overstated, and the trial detail is thin. But strip that back and the shape is impressive: a New Zealand company, built on university research and a single homegrown ingredient, has posted a credible clinical result inside a market forecast to grow from US$54.5 billion in 2024 to US$324.5 billion by 2035.
Calocurb is not claiming to be the miracle jab. It is claiming to be the affordable, plant-based, no-prescription option for the third of New Zealand adults who are obese and cannot access or afford the pharmaceutical alternative. Given where Pharmac has landed, that is a market with a lot of room in it, and a Motueka hops extract is well placed to take a piece.
Sources
- Sarah Kennedy: Calocurb CEO on the research into a natural alternative to Ozempic (2026-07-21)
- Wegovy and Mounjaro for weight loss not funded – Pharmac (2026-05-14)
- A bitter pill – weight loss drugs explained (2026-01-12)
- New Zealand’s Wegovy and Ozempic alternative Calocurb says it’ll double its business with new US deal